share_log

Atara Biotherapeutics (NASDAQ:ATRA) Research Coverage Started at EF Hutton Acquisition Co. I

Atara Biotherapeutics (NASDAQ:ATRA) Research Coverage Started at EF Hutton Acquisition Co. I

阿塔拉生物治療學（NASDAQ：ATRA）在 EF 赫頓收購公司開始研究報導。我
kopsource ·  2023/01/09 02:21

EF Hutton Acquisition Co. I assumed coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) in a report issued on Thursday, Benzinga reports. The brokerage issued a buy rating and a $25.00 target price on the biotechnology company's stock.

據Benzinga報道，我在週四發佈的一份報告中假設了Atara BioTreateutics(納斯達克：ATRA-GET Rating)的股票。該經紀公司對這家生物技術公司的股票發佈了買入評級和25.00美元的目標價。

Separately, StockNews.com assumed coverage on Atara Biotherapeutics in a research report on Wednesday, October 12th. They issued a hold rating for the company. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Atara Biotherapeutics currently has an average rating of Hold and a consensus price target of $19.50.

另外，StockNews.com在10月12日星期三的一份研究報告中對Atara BioTreateutics進行了報道。他們對該公司發佈了持有評級。兩名分析師對該股的評級為賣出，三名分析師給出了持有評級，三名分析師給出了該公司的買入評級。根據MarketBeat的數據，Atara BioTreateutics目前的平均評級為持有，共識目標價為19.50美元。

Get
到達
Atara Biotherapeutics
Atara生物治療學
alerts:
警報：

Atara Biotherapeutics Stock Performance

Atara BioTreatetics股票表現

Shares of NASDAQ:ATRA opened at $3.50 on Thursday. Atara Biotherapeutics has a fifty-two week low of $2.83 and a fifty-two week high of $16.44. The business has a 50-day simple moving average of $4.08 and a two-hundred day simple moving average of $4.44. The firm has a market cap of $332.08 million, a price-to-earnings ratio of -1.42 and a beta of 1.08.

納斯達克：ATRA週四開盤報3.5美元。Atara BioTreateutics的股價為2.83美元，為52周低點，52周高點為16.44美元。該業務的50日簡單移動均線切入位在4.08美元，200日簡單移動均線切入位在4.44美元。該公司市值為3.3208億美元，市盈率為-1.42，貝塔係數為1.08。

Insider Buying and Selling at Atara Biotherapeutics

Atara BioTreatetics的內幕買賣

In other Atara Biotherapeutics news, CFO Utpal Koppikar sold 6,255 shares of the business's stock in a transaction dated Wednesday, November 16th. The stock was sold at an average price of $4.49, for a total transaction of $28,084.95. Following the completion of the sale, the chief financial officer now directly owns 191,334 shares in the company, valued at approximately $859,089.66. The transaction was disclosed in a filing with the SEC, which is available at
在Atara BioTreateutics的其他消息中，首席財務官Utpal Koppikar在11月16日星期三的交易中出售了6255股該公司的股票。該股以4.49美元的平均價格出售，總成交金額為28084.95美元。出售完成後，首席財務官現在直接擁有該公司191,334股，價值約859,089.66美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可在
the SEC website
美國證券交易委員會網站
. In other Atara Biotherapeutics news, CEO Pascal Touchon sold 15,591 shares of the business's stock in a transaction dated Wednesday, November 16th. The stock was sold at an average price of $4.49, for a total transaction of $70,003.59. Following the completion of the sale, the chief executive officer now directly owns 441,696 shares in the company, valued at approximately $1,983,215.04. The transaction was disclosed in a filing with the SEC, which is available at
。在Atara BioTreateutics的其他消息中，首席執行官Pascal Touchon在11月16日星期三的交易中出售了15,591股Atara BioTreateutics股票。該股以4.49美元的平均價格出售，總成交金額為70,003.59美元。出售完成後，行政總裁現直接持有該公司441,696股股份，價值約1,983,215.04美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可在
the SEC website
美國證券交易委員會網站
. Also, CFO Utpal Koppikar sold 6,255 shares of the business's stock in a transaction that occurred on Wednesday, November 16th. The shares were sold at an average price of $4.49, for a total value of $28,084.95. Following the transaction, the chief financial officer now owns 191,334 shares of the company's stock, valued at $859,089.66. The disclosure for this sale can be found
。此外，首席財務官Utpal Koppikar在11月16日星期三的一筆交易中出售了6255股該公司的股票。這些股票的平均價格為4.49美元，總價值為28,084.95美元。交易完成後，這位首席財務官現在擁有191,334股公司股票，價值859,089.66美元。關於這次銷售的披露可以找到
here
這裏
. Insiders sold a total of 29,800 shares of company stock worth $133,802 in the last three months. 4.00% of the stock is currently owned by company insiders.
。在過去的三個月裏，內部人士總共出售了29,800股公司股票，價值133,802美元。4.00%的股份目前由公司內部人士持有。

Institutional Inflows and Outflows

機構資金流入和流出

A number of hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its stake in shares of Atara Biotherapeutics by 117.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 642,158 shares of the biotechnology company's stock valued at $2,427,000 after acquiring an additional 347,261 shares during the period. Balyasny Asset Management LLC grew its stake in shares of Atara Biotherapeutics by 213.3% during the 3rd quarter. Balyasny Asset Management LLC now owns 58,472 shares of the biotechnology company's stock valued at $221,000 after acquiring an additional 39,806 shares during the period. BNP Paribas Arbitrage SNC grew its stake in shares of Atara Biotherapeutics by 637.5% during the 3rd quarter. BNP Paribas Arbitrage SNC now owns 198,267 shares of the biotechnology company's stock valued at $749,000 after acquiring an additional 171,382 shares during the period. Alliancebernstein L.P. grew its stake in shares of Atara Biotherapeutics by 43.4% during the 3rd quarter. Alliancebernstein L.P. now owns 107,040 shares of the biotechnology company's stock valued at $405,000 after acquiring an additional 32,400 shares during the period. Finally, State Street Corp grew its stake in shares of Atara Biotherapeutics by 30.1% during the 3rd quarter. State Street Corp now owns 8,097,353 shares of the biotechnology company's stock valued at $30,608,000 after acquiring an additional 1,875,667 shares during the period.

一些對衝基金最近改變了他們在該股的頭寸。紐約梅隆銀行(Bank Of New York Mellon Corp)在第三季度增持了Atara BioTreateutics股票117.8%。紐約梅隆銀行(Bank Of New York Mellon Corp)目前持有這家生物技術公司642,158股票，價值2,427,000美元，在此期間又購買了347,261股票。Balyasny Asset Management LLC在第三季度將其在Atara BioTreateutics的股份增加了213.3%。Balyasny Asset Management LLC在此期間額外收購了39,806股，現在擁有58,472股這家生物技術公司的股票，價值221,000美元。法國巴黎銀行套利SNC在第三季度將其在Atara BioTreateutics的股份增加了637.5%。法國巴黎銀行套利SNC現在擁有這家生物技術公司198,267股股票，價值74.9萬美元，在此期間又購買了171,382股。第三季度，聯合伯恩斯坦公司在Atara BioTreateutics的持股增加了43.4%。在此期間，聯合伯恩斯坦公司又購入了32,400股，現在擁有107,040股這家生物技術公司的股票，價值40.5萬美元。最後，道富集團在第三季度增持了Atara BioTreateutics的股份30.1%。道富集團目前持有這家生物技術公司8,097,353股股票，價值30,608,000美元，在此期間又收購了1,875,667股。

Atara Biotherapeutics Company Profile

Atara生物療法公司簡介

(Get Rating)

(獲取評級)

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.

Atara BioTreateutics，Inc.是一家現成的T細胞免疫治療公司，在美國開發癌症、自身免疫和病毒疾病患者的治療方法。該公司正在開發Tabelecleucel，這是一種T細胞免疫療法，處於第三階段臨牀試驗，用於治療EB病毒(EBV)驅動的移植後淋巴增生性疾病，以及血液和實體腫瘤，包括鼻咽癌。

Recommended Stories

推薦故事

  • Get a free copy of the StockNews.com research report on Atara Biotherapeutics (ATRA)
  • Will LI Auto Be the Least Hated Chinese EV Stock in 2023?
  • Which Streaming Service Stock is Best in 2023?
  • Here's Why Snap Stock Can Double in 2023
  • MarketBeat: Week in Review 01/02-01/06
  • Why is the CrowdStrike Stock Price Struggling?
  • 免費獲取StockNews.com關於Atara生物療法(ATRA)的研究報告
  • 理想汽車會成為2023年最不招人恨的中國電動汽車股嗎？
  • 哪種流媒體服務股票是2023年最好的？
  • 以下是Snap股票在2023年翻一番的原因
  • MarketBeat：回顧中的一週01/02-01/06
  • 為什麼CrowdStrike的股價舉步維艱？

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

獲得Atara生物療法日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Atara BioTreateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論